Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,786
archived clinical trials in
Dermatology

Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated:  2/7/2017
Clinical Research Facility
1064
mi
from
Charleston, SC
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Clinical Research Facility
1064
mi
from
Charleston, SC
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated:  2/7/2017
Clinical Research Facility
889
mi
from
Greer, SC
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Clinical Research Facility
889
mi
from
Greer, SC
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated:  2/7/2017
Clinical Research Facility
353
mi
from
Arlington, TX
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Clinical Research Facility
353
mi
from
Arlington, TX
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated:  2/7/2017
Clinical Research Facility
522
mi
from
Austin, TX
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Clinical Research Facility
522
mi
from
Austin, TX
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated:  2/7/2017
Clinical Research Facility
569
mi
from
Houston, TX
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Clinical Research Facility
569
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated:  2/7/2017
Clinical Research Facility
587
mi
from
Webster, TX
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Clinical Research Facility
587
mi
from
Webster, TX
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated:  2/7/2017
Clinical Research Facility
1111
mi
from
Richmond, VA
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Clinical Research Facility
1111
mi
from
Richmond, VA
Click here to add this to my saved trials
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated:  2/7/2017
Clinical Research Facility
1410
mi
from
Seattle, WA
Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Status: Enrolling
Updated: 2/7/2017
Clinical Research Facility
1410
mi
from
Seattle, WA
Click here to add this to my saved trials
Study To Evaluate The Efficacy Of Tofacitinib In Moderate To Severe Alopecia Areata, Totalis And Universalis
An Open-Label Pilot Study To Evaluate The Efficacy Of Tofacitinib In Moderate To Severe Alopecia Areata, Totalis And Universalis
Status: Enrolling
Updated:  2/14/2017
Columbia University Medical Center
1286
mi
from
New York, NY
Study To Evaluate The Efficacy Of Tofacitinib In Moderate To Severe Alopecia Areata, Totalis And Universalis
An Open-Label Pilot Study To Evaluate The Efficacy Of Tofacitinib In Moderate To Severe Alopecia Areata, Totalis And Universalis
Status: Enrolling
Updated: 2/14/2017
Columbia University Medical Center
1286
mi
from
New York, NY
Click here to add this to my saved trials
NB-UVB and PUVA Vitiligo Study
Prospective Open Parallel Right to Left Bilateral Study Comparing Narrowband Ultraviolet B Alone Versus Narrowband Ultraviolet B and Psoralen Plus Ultraviolet A for the Treatment of Vitiligo
Status: Enrolling
Updated:  2/22/2017
Henry Ford Dermatology
841
mi
from
Detroit, MI
NB-UVB and PUVA Vitiligo Study
Prospective Open Parallel Right to Left Bilateral Study Comparing Narrowband Ultraviolet B Alone Versus Narrowband Ultraviolet B and Psoralen Plus Ultraviolet A for the Treatment of Vitiligo
Status: Enrolling
Updated: 2/22/2017
Henry Ford Dermatology
841
mi
from
Detroit, MI
Click here to add this to my saved trials
Correlates of Oral Human Papillomavirus Infection in Adolescents and Young Adults With Behaviorally Acquired HIV
Behavioral, Immunologic and Virologic Correlates of Oral Human Papillomavirus Infection in Adolescents and Young Adults With Behaviorally Acquired HIV-Infection
Status: Enrolling
Updated:  2/27/2017
University of Colorado Denver
402
mi
from
Aurora, CO
Correlates of Oral Human Papillomavirus Infection in Adolescents and Young Adults With Behaviorally Acquired HIV
Behavioral, Immunologic and Virologic Correlates of Oral Human Papillomavirus Infection in Adolescents and Young Adults With Behaviorally Acquired HIV-Infection
Status: Enrolling
Updated: 2/27/2017
University of Colorado Denver
402
mi
from
Aurora, CO
Click here to add this to my saved trials
Correlates of Oral Human Papillomavirus Infection in Adolescents and Young Adults With Behaviorally Acquired HIV
Behavioral, Immunologic and Virologic Correlates of Oral Human Papillomavirus Infection in Adolescents and Young Adults With Behaviorally Acquired HIV-Infection
Status: Enrolling
Updated:  2/27/2017
Johns Hopkins University
1148
mi
from
Baltimore, MD
Correlates of Oral Human Papillomavirus Infection in Adolescents and Young Adults With Behaviorally Acquired HIV
Behavioral, Immunologic and Virologic Correlates of Oral Human Papillomavirus Infection in Adolescents and Young Adults With Behaviorally Acquired HIV-Infection
Status: Enrolling
Updated: 2/27/2017
Johns Hopkins University
1148
mi
from
Baltimore, MD
Click here to add this to my saved trials
Correlates of Oral Human Papillomavirus Infection in Adolescents and Young Adults With Behaviorally Acquired HIV
Behavioral, Immunologic and Virologic Correlates of Oral Human Papillomavirus Infection in Adolescents and Young Adults With Behaviorally Acquired HIV-Infection
Status: Enrolling
Updated:  2/27/2017
The Fenway Institute
1444
mi
from
Boston, MA
Correlates of Oral Human Papillomavirus Infection in Adolescents and Young Adults With Behaviorally Acquired HIV
Behavioral, Immunologic and Virologic Correlates of Oral Human Papillomavirus Infection in Adolescents and Young Adults With Behaviorally Acquired HIV-Infection
Status: Enrolling
Updated: 2/27/2017
The Fenway Institute
1444
mi
from
Boston, MA
Click here to add this to my saved trials
Correlates of Oral Human Papillomavirus Infection in Adolescents and Young Adults With Behaviorally Acquired HIV
Behavioral, Immunologic and Virologic Correlates of Oral Human Papillomavirus Infection in Adolescents and Young Adults With Behaviorally Acquired HIV-Infection
Status: Enrolling
Updated:  2/27/2017
Children's Hospital of Michigan
841
mi
from
Detroit, MI
Correlates of Oral Human Papillomavirus Infection in Adolescents and Young Adults With Behaviorally Acquired HIV
Behavioral, Immunologic and Virologic Correlates of Oral Human Papillomavirus Infection in Adolescents and Young Adults With Behaviorally Acquired HIV-Infection
Status: Enrolling
Updated: 2/27/2017
Children's Hospital of Michigan
841
mi
from
Detroit, MI
Click here to add this to my saved trials
Correlates of Oral Human Papillomavirus Infection in Adolescents and Young Adults With Behaviorally Acquired HIV
Behavioral, Immunologic and Virologic Correlates of Oral Human Papillomavirus Infection in Adolescents and Young Adults With Behaviorally Acquired HIV-Infection
Status: Enrolling
Updated:  2/27/2017
Baylor College of Medicine
569
mi
from
Houston, TX
Correlates of Oral Human Papillomavirus Infection in Adolescents and Young Adults With Behaviorally Acquired HIV
Behavioral, Immunologic and Virologic Correlates of Oral Human Papillomavirus Infection in Adolescents and Young Adults With Behaviorally Acquired HIV-Infection
Status: Enrolling
Updated: 2/27/2017
Baylor College of Medicine
569
mi
from
Houston, TX
Click here to add this to my saved trials
Compression Headband Use to Prevent Hair Loss During Whole Brain Radiotherapy
Feasibility Clinical Study of Compression Headband Use to Prevent Hair Loss During Whole Brain Radiotherapy
Status: Enrolling
Updated:  2/27/2017
Dept. of Radiation Oncology, University of Rochester, Med Center
1121
mi
from
Rochester, NY
Compression Headband Use to Prevent Hair Loss During Whole Brain Radiotherapy
Feasibility Clinical Study of Compression Headband Use to Prevent Hair Loss During Whole Brain Radiotherapy
Status: Enrolling
Updated: 2/27/2017
Dept. of Radiation Oncology, University of Rochester, Med Center
1121
mi
from
Rochester, NY
Click here to add this to my saved trials
BM Collection From NICU Infants for Composition
Collection and Characterization of Premature Infants Feces for Identification of Factors Contributing to Skin Irritation
Status: Enrolling
Updated:  2/28/2017
Rady Children's Hospital
1139
mi
from
San Diego, CA
BM Collection From NICU Infants for Composition
Collection and Characterization of Premature Infants Feces for Identification of Factors Contributing to Skin Irritation
Status: Enrolling
Updated: 2/28/2017
Rady Children's Hospital
1139
mi
from
San Diego, CA
Click here to add this to my saved trials
Biological Effects of LEO 43204 in Actinic Keratosis
Biological Effects of LEO 43204 in Actinic Keratosis Assessed by Histopathology
Status: Enrolling
Updated:  3/2/2017
Beacon Clinical Research
1446
mi
from
Quincy, MA
Biological Effects of LEO 43204 in Actinic Keratosis
Biological Effects of LEO 43204 in Actinic Keratosis Assessed by Histopathology
Status: Enrolling
Updated: 3/2/2017
Beacon Clinical Research
1446
mi
from
Quincy, MA
Click here to add this to my saved trials
Biological Effects of LEO 43204 in Actinic Keratosis
Biological Effects of LEO 43204 in Actinic Keratosis Assessed by Histopathology
Status: Enrolling
Updated:  3/2/2017
Long Island Skin Cancer and Dermatology Surgery
1328
mi
from
Smithtown, NY
Biological Effects of LEO 43204 in Actinic Keratosis
Biological Effects of LEO 43204 in Actinic Keratosis Assessed by Histopathology
Status: Enrolling
Updated: 3/2/2017
Long Island Skin Cancer and Dermatology Surgery
1328
mi
from
Smithtown, NY
Click here to add this to my saved trials
Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients
A Randomized, Double-blind, Placebo Controlled, Multiple Dose Study to Evaluate the Clinical Efficacy, Safety, Tolerability, Dose Relation, Pharmacokinetics and Pharmacodynamics of CJM112 in Moderate to Severe Chronic Hidradenitis Suppurativa Patients
Status: Enrolling
Updated:  3/14/2017
Novartis Investigative site
1177
mi
from
Los Angeles, CA
Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients
A Randomized, Double-blind, Placebo Controlled, Multiple Dose Study to Evaluate the Clinical Efficacy, Safety, Tolerability, Dose Relation, Pharmacokinetics and Pharmacodynamics of CJM112 in Moderate to Severe Chronic Hidradenitis Suppurativa Patients
Status: Enrolling
Updated: 3/14/2017
Novartis Investigative site
1177
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients
A Randomized, Double-blind, Placebo Controlled, Multiple Dose Study to Evaluate the Clinical Efficacy, Safety, Tolerability, Dose Relation, Pharmacokinetics and Pharmacodynamics of CJM112 in Moderate to Severe Chronic Hidradenitis Suppurativa Patients
Status: Enrolling
Updated:  3/14/2017
Novartis Investigative Site
1126
mi
from
Ormond Beach, FL
Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients
A Randomized, Double-blind, Placebo Controlled, Multiple Dose Study to Evaluate the Clinical Efficacy, Safety, Tolerability, Dose Relation, Pharmacokinetics and Pharmacodynamics of CJM112 in Moderate to Severe Chronic Hidradenitis Suppurativa Patients
Status: Enrolling
Updated: 3/14/2017
Novartis Investigative Site
1126
mi
from
Ormond Beach, FL
Click here to add this to my saved trials
Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients
A Randomized, Double-blind, Placebo Controlled, Multiple Dose Study to Evaluate the Clinical Efficacy, Safety, Tolerability, Dose Relation, Pharmacokinetics and Pharmacodynamics of CJM112 in Moderate to Severe Chronic Hidradenitis Suppurativa Patients
Status: Enrolling
Updated:  3/14/2017
Novartis Investigational Site
1111
mi
from
Tampa, FL
Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients
A Randomized, Double-blind, Placebo Controlled, Multiple Dose Study to Evaluate the Clinical Efficacy, Safety, Tolerability, Dose Relation, Pharmacokinetics and Pharmacodynamics of CJM112 in Moderate to Severe Chronic Hidradenitis Suppurativa Patients
Status: Enrolling
Updated: 3/14/2017
Novartis Investigational Site
1111
mi
from
Tampa, FL
Click here to add this to my saved trials
Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients
A Randomized, Double-blind, Placebo Controlled, Multiple Dose Study to Evaluate the Clinical Efficacy, Safety, Tolerability, Dose Relation, Pharmacokinetics and Pharmacodynamics of CJM112 in Moderate to Severe Chronic Hidradenitis Suppurativa Patients
Status: Enrolling
Updated:  3/14/2017
Novartis Investigative Site
803
mi
from
Atlanta, GA
Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients
A Randomized, Double-blind, Placebo Controlled, Multiple Dose Study to Evaluate the Clinical Efficacy, Safety, Tolerability, Dose Relation, Pharmacokinetics and Pharmacodynamics of CJM112 in Moderate to Severe Chronic Hidradenitis Suppurativa Patients
Status: Enrolling
Updated: 3/14/2017
Novartis Investigative Site
803
mi
from
Atlanta, GA
Click here to add this to my saved trials
Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients
A Randomized, Double-blind, Placebo Controlled, Multiple Dose Study to Evaluate the Clinical Efficacy, Safety, Tolerability, Dose Relation, Pharmacokinetics and Pharmacodynamics of CJM112 in Moderate to Severe Chronic Hidradenitis Suppurativa Patients
Status: Enrolling
Updated:  3/14/2017
Novartis Investigative Site
642
mi
from
Indianapolis, IN
Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients
A Randomized, Double-blind, Placebo Controlled, Multiple Dose Study to Evaluate the Clinical Efficacy, Safety, Tolerability, Dose Relation, Pharmacokinetics and Pharmacodynamics of CJM112 in Moderate to Severe Chronic Hidradenitis Suppurativa Patients
Status: Enrolling
Updated: 3/14/2017
Novartis Investigative Site
642
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients
A Randomized, Double-blind, Placebo Controlled, Multiple Dose Study to Evaluate the Clinical Efficacy, Safety, Tolerability, Dose Relation, Pharmacokinetics and Pharmacodynamics of CJM112 in Moderate to Severe Chronic Hidradenitis Suppurativa Patients
Status: Enrolling
Updated:  3/14/2017
Novartis Investigative Site
1122
mi
from
Rockville, MD
Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients
A Randomized, Double-blind, Placebo Controlled, Multiple Dose Study to Evaluate the Clinical Efficacy, Safety, Tolerability, Dose Relation, Pharmacokinetics and Pharmacodynamics of CJM112 in Moderate to Severe Chronic Hidradenitis Suppurativa Patients
Status: Enrolling
Updated: 3/14/2017
Novartis Investigative Site
1122
mi
from
Rockville, MD
Click here to add this to my saved trials
Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients
A Randomized, Double-blind, Placebo Controlled, Multiple Dose Study to Evaluate the Clinical Efficacy, Safety, Tolerability, Dose Relation, Pharmacokinetics and Pharmacodynamics of CJM112 in Moderate to Severe Chronic Hidradenitis Suppurativa Patients
Status: Enrolling
Updated:  3/14/2017
Novartis Investigative site
1444
mi
from
Boston, MA
Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients
A Randomized, Double-blind, Placebo Controlled, Multiple Dose Study to Evaluate the Clinical Efficacy, Safety, Tolerability, Dose Relation, Pharmacokinetics and Pharmacodynamics of CJM112 in Moderate to Severe Chronic Hidradenitis Suppurativa Patients
Status: Enrolling
Updated: 3/14/2017
Novartis Investigative site
1444
mi
from
Boston, MA
Click here to add this to my saved trials
Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients
A Randomized, Double-blind, Placebo Controlled, Multiple Dose Study to Evaluate the Clinical Efficacy, Safety, Tolerability, Dose Relation, Pharmacokinetics and Pharmacodynamics of CJM112 in Moderate to Severe Chronic Hidradenitis Suppurativa Patients
Status: Enrolling
Updated:  3/14/2017
Novartis Investigative Site
257
mi
from
Omaha, NE
Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients
A Randomized, Double-blind, Placebo Controlled, Multiple Dose Study to Evaluate the Clinical Efficacy, Safety, Tolerability, Dose Relation, Pharmacokinetics and Pharmacodynamics of CJM112 in Moderate to Severe Chronic Hidradenitis Suppurativa Patients
Status: Enrolling
Updated: 3/14/2017
Novartis Investigative Site
257
mi
from
Omaha, NE
Click here to add this to my saved trials
Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients
A Randomized, Double-blind, Placebo Controlled, Multiple Dose Study to Evaluate the Clinical Efficacy, Safety, Tolerability, Dose Relation, Pharmacokinetics and Pharmacodynamics of CJM112 in Moderate to Severe Chronic Hidradenitis Suppurativa Patients
Status: Enrolling
Updated:  3/14/2017
Novartis Investigative Site
615
mi
from
Nashville, TN
Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients
A Randomized, Double-blind, Placebo Controlled, Multiple Dose Study to Evaluate the Clinical Efficacy, Safety, Tolerability, Dose Relation, Pharmacokinetics and Pharmacodynamics of CJM112 in Moderate to Severe Chronic Hidradenitis Suppurativa Patients
Status: Enrolling
Updated: 3/14/2017
Novartis Investigative Site
615
mi
from
Nashville, TN
Click here to add this to my saved trials
Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients
A Randomized, Double-blind, Placebo Controlled, Multiple Dose Study to Evaluate the Clinical Efficacy, Safety, Tolerability, Dose Relation, Pharmacokinetics and Pharmacodynamics of CJM112 in Moderate to Severe Chronic Hidradenitis Suppurativa Patients
Status: Enrolling
Updated:  3/14/2017
Novartis Investigative Site
4788
mi
from
Roskilde,
Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients
A Randomized, Double-blind, Placebo Controlled, Multiple Dose Study to Evaluate the Clinical Efficacy, Safety, Tolerability, Dose Relation, Pharmacokinetics and Pharmacodynamics of CJM112 in Moderate to Severe Chronic Hidradenitis Suppurativa Patients
Status: Enrolling
Updated: 3/14/2017
Novartis Investigative Site
4788
mi
from
Roskilde,
Click here to add this to my saved trials
Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis
Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis: A Phase 2a, Single-centered, Randomized, Placebo-controlled, Double-blind, Proof-of-concept Pilot Study.
Status: Enrolling
Updated:  3/15/2017
Hospital for Special Surgery
1289
mi
from
New York, NY
Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis
Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis: A Phase 2a, Single-centered, Randomized, Placebo-controlled, Double-blind, Proof-of-concept Pilot Study.
Status: Enrolling
Updated: 3/15/2017
Hospital for Special Surgery
1289
mi
from
New York, NY
Click here to add this to my saved trials
Nanopulse Efficacy Study for the Treatment of Common Warts
Nanopulse Efficacy Study for the Treatment of Common Warts
Status: Enrolling
Updated:  3/28/2017
Huntington Medical Foundation
1162
mi
from
Pasadena, CA
Nanopulse Efficacy Study for the Treatment of Common Warts
Nanopulse Efficacy Study for the Treatment of Common Warts
Status: Enrolling
Updated: 3/28/2017
Huntington Medical Foundation
1162
mi
from
Pasadena, CA
Click here to add this to my saved trials
Prospective Study of 2 mm Margins for the Biopsy of Dysplastic Nevi
Prospective Study of 2 mm Margins for the Biopsy of Dysplastic Nevi
Status: Enrolling
Updated:  3/30/2017
Laura & Isaac Perlmutter Cancer Center & NYU Langone Medical Center
1288
mi
from
New York, NY
Prospective Study of 2 mm Margins for the Biopsy of Dysplastic Nevi
Prospective Study of 2 mm Margins for the Biopsy of Dysplastic Nevi
Status: Enrolling
Updated: 3/30/2017
Laura & Isaac Perlmutter Cancer Center & NYU Langone Medical Center
1288
mi
from
New York, NY
Click here to add this to my saved trials
Exparel as a Nerve Block for Severe Hand Pain
Chemical Sympathectomy Following Peripheral Nerve Block With Liposomal Bupivacaine
Status: Enrolling
Updated:  4/3/2017
Ochsner Clinic Foundation
694
mi
from
New Orleans, LA
Exparel as a Nerve Block for Severe Hand Pain
Chemical Sympathectomy Following Peripheral Nerve Block With Liposomal Bupivacaine
Status: Enrolling
Updated: 4/3/2017
Ochsner Clinic Foundation
694
mi
from
New Orleans, LA
Click here to add this to my saved trials
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated:  4/5/2017
Advances In Medicine
1077
mi
from
Rancho Mirage, CA
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated: 4/5/2017
Advances In Medicine
1077
mi
from
Rancho Mirage, CA
Click here to add this to my saved trials
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated:  4/5/2017
Delaware Medical Care Associates, LLC
1193
mi
from
Newark, DE
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated: 4/5/2017
Delaware Medical Care Associates, LLC
1193
mi
from
Newark, DE
Click here to add this to my saved trials
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated:  4/5/2017
University of Illinois at Chicago
610
mi
from
Chicago, IL
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated: 4/5/2017
University of Illinois at Chicago
610
mi
from
Chicago, IL
Click here to add this to my saved trials
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated:  4/5/2017
LaPorte County Institute for Clinical Research Inc.
641
mi
from
Michigan City, IN
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated: 4/5/2017
LaPorte County Institute for Clinical Research Inc.
641
mi
from
Michigan City, IN
Click here to add this to my saved trials
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated:  4/5/2017
University of Kentucky
725
mi
from
Lexington, KY
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated: 4/5/2017
University of Kentucky
725
mi
from
Lexington, KY
Click here to add this to my saved trials
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated:  4/5/2017
University of Toledo College of Medicine
804
mi
from
Toledo, OH
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated: 4/5/2017
University of Toledo College of Medicine
804
mi
from
Toledo, OH
Click here to add this to my saved trials
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated:  4/5/2017
University of Pittsburgh
973
mi
from
Pittsburgh, PA
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated: 4/5/2017
University of Pittsburgh
973
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated:  4/5/2017
Medical College of Wisconsin
636
mi
from
Milwaukee, WI
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated: 4/5/2017
Medical College of Wisconsin
636
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated:  4/5/2017
UCLA Division of Rheumatology
1179
mi
from
Los Angeles, CA
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated: 4/5/2017
UCLA Division of Rheumatology
1179
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated:  4/5/2017
Georgetown University School of Medicine
1127
mi
from
Washington,
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated: 4/5/2017
Georgetown University School of Medicine
1127
mi
from
Washington,
Click here to add this to my saved trials
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated:  4/5/2017
USF Health Faculty Office Building-FOB
1117
mi
from
Tampa, FL
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated: 4/5/2017
USF Health Faculty Office Building-FOB
1117
mi
from
Tampa, FL
Click here to add this to my saved trials
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated:  4/5/2017
Arthritis Research and Treatment Center
816
mi
from
Stockbridge, GA
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated: 4/5/2017
Arthritis Research and Treatment Center
816
mi
from
Stockbridge, GA
Click here to add this to my saved trials
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated:  4/5/2017
Louisiana State Univ.
429
mi
from
Shreveport, LA
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated: 4/5/2017
Louisiana State Univ.
429
mi
from
Shreveport, LA
Click here to add this to my saved trials
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated:  4/5/2017
Boston University of Medicine BUMC
1443
mi
from
Boston, MA
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated: 4/5/2017
Boston University of Medicine BUMC
1443
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated:  4/5/2017
University of Michigan
808
mi
from
Ann Arbor, MI
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated: 4/5/2017
University of Michigan
808
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated:  4/5/2017
UMDNJ-Robert Wood Johnson Medical School Clinical Research Center
1265
mi
from
New Brunswick, NJ
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated: 4/5/2017
UMDNJ-Robert Wood Johnson Medical School Clinical Research Center
1265
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated:  4/5/2017
North Shore-LIJ Health System-Division of Rheumatology
1301
mi
from
Great Neck, NY
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated: 4/5/2017
North Shore-LIJ Health System-Division of Rheumatology
1301
mi
from
Great Neck, NY
Click here to add this to my saved trials